Know Cancer

forgot password

T-Regulatory Cell Kinetics Post Transplant For Patients Undergoing Matched Sibling Stem Cell Transplantation

64 Years
Open (Enrolling)
Leukemia, Cancer, Lymphoma, Lymphoma, Hodgkin, Lymphoma, Non-Hodgkin

Thank you

Trial Information

T-Regulatory Cell Kinetics Post Transplant For Patients Undergoing Matched Sibling Stem Cell Transplantation

Before the transplant we will test the patients blood for viruses which can cause problems
after the transplant. These viruses include Hepatitis B, (which causes liver damage),
cytomegalovirus, (which causes lung disease) and HIV (which causes AIDS). If the patient is
positive for the AIDS virus, they will not be able to undertake the transplant.

The patient will be given 6 doses of chemotherapy with a drug called Ara C in high doses
(every 12 hours) which will begin 8 days before their stem cell transplant. Then, another
chemotherapy drug called cyclophosphamide will be given in high doses by vein for two days
on the 7th and 6th days before their transplant. A drug called MESNA will be given with
cyclophosphamide. MESNA is used to decrease the side effects caused by cyclophosphamide.
Radiation treatment will be given to the entire body on each day for 4 days before the
transplant. This will be done 2 times a day for 4 days. The chemotherapy and radiation
treatment will last 8 days. The patient will receive extra radiation treatment if they have
certain diseases (central nervous system (CNS) disease, testicular disease or other focal
(localized) disease).

The day after the radiation treatment is completed; the patient will receive the healthy
stem cells by vein. Once in the bloodstream, these stem cells will go to the bone marrow and
should begin to grow

In prevention of GVHD, the patient will also receive medicine called FK506 as well as low
dose methotrexate. The FK506 will be given intravenously (through the vein) initially
starting 2 days before the transplant and later by mouth (when they are able to take oral
medications). This drug will be given each day for several weeks. Four doses of low dose
methotrexate will be given intravenously. The methotrexate will be given on the day after
the transplant, 3, 6 and 11 days after the transplant. If the GVHD cannot be controlled with
FK506, other medicines may need to be given. Your doctor will describe these medicines at
that time.

After the patient has their stem cell transplant, we would like to collect some blood at
different time points after the transplantation in order to study how regulatory T cells
work and grow after a stem cell transplant.

To study how these cells are working in the system, blood samples will be taken each month
for six months, at nine months, at one year, 2 years and 3 years following transplant.
Approximately 6-8 teaspoons of blood will be collected each time. The total blood drawn for
this study over three years should not exceed 1 and 3/4 cups. This amount is considered safe
in adults. The amount of blood collected will be decreased in children and/or in patients
where this amount of blood collection would not be appropriate. If the patient has a central
line, the blood will be taken from it, so that extra needle sticks should not be needed. If
the patient does not have a central line, they will need to have one placed. This will be a
separate procedure for which the patient will sign a separate consent form. The patient will
need to come to the clinic on the days of blood drawing and to be seen at Texas Children's
Cancer Center.

Inclusion Criteria


- Patients with acute or chronic leukemia or advanced Hodgkin or non Hodgkin lymphoma
or myelodysplastic/myeloproliferative disease who are unlikely to be cured by
standard chemotherapy treatments. This includes patients who have relapsed after
standard chemotherapy treatments and patients in first remission with unfavorable
prognostic features.

- Patient must have a genotype HLA identical stem cell donor.


- Patients with a life expectancy (less than or equal to 6 weeks) limited by disease
other than leukemia.

- Patients with symptomatic cardiac failure unrelieved by medical therapy or evidence
of significant cardiac dysfunction by echocardiogram (shortening fraction <20%).

- Patients with severe renal disease (i.e., creatinine greater than 3 times normal for

- Patients with pre-existing severe restrictive pulmonary disease (FVC less than 40% of

- Patients with severe hepatic disease (direct bilirubin greater than 3 mg/dl or AST
greater than 500 IU/L).

- Patients with severe personality disorder or mental illness.

- Patients with severe infection that in the estimation of the principal investigator
prohibits the use of ablative chemotherapy.

- Patients who are documented HIV positive.

- Patients with a Karnofsky performance score <60% or Lansky performance score <50%.

NOTE: Patients who would be excluded from treatment on this protocol strictly for
laboratory or performance abnormalities can be included at the principal investigator's
discretion after consultation with the members of the SCT Policy and Procedures Committee.

Type of Study:


Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Measuring the changes in the regulatory T cell population

Outcome Description:

The investigative intent is to determine the changes in numbers and function of the regulatory cell population using the best methods to measure this cell population. The frequency of T cells will be summarized at baseline and each time point of follow-up.

Outcome Time Frame:

1 Year

Safety Issue:


Principal Investigator

Robert Krance, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Baylor College of Medicine


United States: Institutional Review Board

Study ID:




Start Date:

October 2007

Completion Date:

May 2013

Related Keywords:

  • Leukemia
  • Cancer
  • Lymphoma
  • Lymphoma, Hodgkin
  • Lymphoma, Non-Hodgkin
  • Stem Cell Transplant
  • myeloproliferative disease
  • myelodsyplastic disease
  • Leukemia
  • Cancer
  • Lymphoma
  • Lymphoma, Hodgkin
  • Lymphoma, non-Hodgkin
  • Hodgkin Disease
  • Leukemia
  • Lymphoma
  • Lymphoma, Non-Hodgkin



Texas Children's Hospital Houston, Texas